Website: N/A
Stock Symbol: NASDAQ: VNDA
Market Value: N/A (in millions)

We are a biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with exclusive worldwide commercial rights to three product candidates in clinical development. We believe that each of our product candidates will address a large market with significant unmet medical needs by offering advantages over currently available therapies. Our product portfolio includes: • Fiaptatm (iloperidone), a compound for the treatment of schizophrenia and bipolar disorder. On November 27, 2007 the United States Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for Fiaptatm for the treatment of schizophrenia. Acceptance of the NDA confirms that the application is sufficiently complete for FDA review.